Literature DB >> 19159428

Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model.

Kaori Shimazaki1, Ann M Chan, Raymond J Moniz, Madhuri Wadehra, Agnes Nagy, Catherine P Coulam, Sergey Mareninov, Eric M Lepin, Anna M Wu, Kathleen A Kelly, Jonathan Braun, Lynn K Gordon.   

Abstract

New methods are needed to eradicate or prevent Chlamydia trachomatis infections. Blockade of epithelial membrane protein 2 (EMP2) by genetic silencing or neutralizing polyclonal antibody reduced chlamydial infectivity in vitro. This study tests the prediction that recombinant anti-EMP2 diabody could reduce early chlamydial infection of the genital tract in vivo. In a murine infection model, pretreatment with anti-EMP2 diabody, as compared with control diabody, significantly reduced bacterial load, tissue production of inflammatory cytokines, recruitment of polymorphonuclear leukocytes, and local tissue inflammation. These findings support EMP2 as a potential preventative and therapeutic target for genital chlamydial infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19159428      PMCID: PMC3321642          DOI: 10.1111/j.1574-695X.2008.00525.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  39 in total

Review 1.  Chlamydia--host cell interactions: recent advances on bacterial entry and intracellular development.

Authors:  Alice Dautry-Varsat; María Eugenia Balañá; Benjamin Wyplosz
Journal:  Traffic       Date:  2004-08       Impact factor: 6.215

Review 2.  Passive antibody therapy for infectious diseases.

Authors:  Arturo Casadevall; Ekaterina Dadachova; Liise-anne Pirofski
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

3.  Infectivity of Chlamydia trachomatis serovar LGV but not E is dependent on host cell heparan sulfate.

Authors:  M Taraktchoglou; A A Pacey; J E Turnbull; A Eley
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Macromolecular components of the luminal fluid from the bovine uterus.

Authors:  G P Roberts; J M Parker
Journal:  J Reprod Fertil       Date:  1974-10

5.  Field trial of two bivalent trachoma vaccines in children of Punjab Indian villages.

Authors:  S P Dhir; L P Agarwal; R Detels; S P Wang; J T Grayston
Journal:  Am J Ophthalmol       Date:  1967-05       Impact factor: 5.258

6.  Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan.

Authors:  R L Woolridge; J T Grayston; I H Chang; C Y Yang; K H Cheng
Journal:  Am J Ophthalmol       Date:  1967-05       Impact factor: 5.258

7.  The infecting dose of Chlamydia muridarum modulates the innate immune response and ascending infection.

Authors:  Heather K Maxion; Wei Liu; Mi-Hyang Chang; Kathleen A Kelly
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

8.  Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis.

Authors:  Y X Zhang; S Stewart; T Joseph; H R Taylor; H D Caldwell
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

9.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

10.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.

Authors:  Tove Olafsen; Chia-Wei Cheung; Paul J Yazaki; Lin Li; Gobalakrishnan Sundaresan; Sanjiv S Gambhir; Mark A Sherman; Lawrence E Williams; John E Shively; Andrew A Raubitschek; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2004-01       Impact factor: 1.650

View more
  7 in total

1.  Infectivity acts as in vivo selection for maintenance of the chlamydial cryptic plasmid.

Authors:  Marsha Russell; Toni Darville; Kumar Chandra-Kuntal; Bennett Smith; Charles W Andrews; Catherine M O'Connell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Plasmacytoid dendritic cells modulate nonprotective T-cell responses to genital infection by Chlamydia muridarum.

Authors:  Raymond J Moniz; Ann M Chan; Lynn K Gordon; Jonathan Braun; Moshe Arditi; Kathleen A Kelly
Journal:  FEMS Immunol Med Microbiol       Date:  2010-01-19

3.  Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.

Authors:  Maoyong Fu; Erin L Maresh; Robert A Soslow; Mohammad Alavi; Vei Mah; Qin Zhou; Alexia Iasonos; Lee Goodglick; Lynn K Gordon; Jonathan Braun; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2010-08-01       Impact factor: 12.531

4.  Epithelial membrane protein 2 governs transepithelial migration of neutrophils into the airspace.

Authors:  Wan-Chi Lin; Kymberly M Gowdy; Jennifer H Madenspacher; Rachel L Zemans; Kazuko Yamamoto; Miranda Lyons-Cohen; Hideki Nakano; Kyathanahalli Janardhan; Carmen J Williams; Donald N Cook; Joseph P Mizgerd; Michael B Fessler
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

5.  Brucella melitensis and Mycobacterium tuberculosis depict overlapping gene expression patterns induced in infected THP-1 macrophages.

Authors:  M Masoudian; A Derakhshandeh; M M Ghahramani Seno
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

6.  Autophagy induction and PDGFR-β knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection.

Authors:  Sidi Yang; Yannick Traore; Celine Jimenez; Emmanuel A Ho
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

7.  Expression of CXCR3 on Adaptive and Innate Immune Cells Contributes Oviduct Pathology throughout Chlamydia muridarum Infection.

Authors:  Janina Jiang; Heather Maxion; Cheryl I Champion; Guangchao Liu; Kathleen A Kelly
Journal:  J Mucosal Immunol Res       Date:  2017-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.